Home SUBOXONE(R) Film Quality Patient Care Here to Help(R) Program REMS Resources Certification
More affordable than SUBOXONE Tablet.* Preferred by patients.(1) Switch your patients to SUBOXONE Film and help them SAVE. *Learn more
evolving treatment empowering patients

SUBOXONE Practice Management Resources/Forms

In support of your treatment efforts, the SUBOXONE Practice Management Resources were created to help you and your staff prepare for and manage treatment of opioid-dependent patients. Our primary goal is to support you in your efforts to provide Patient-focused Quality Care and to assure appropriate use of SUBOXONE.

How to Use the Practice Management Resources

The resources provided here are organized by practice considerations (preparing to treat with SUBOXONE and working with other professionals) and phases of treatment. To access any of the forms or handouts, simply double-click on the specific handout that you wish to print. This website automatically launches the file in Microsoft® Word or Adobe®Reader®. The program and the website are open simultaneously.

Forms or Handouts in Word. The majority of the forms and handouts are provided as Microsoft® Word documents, allowing you to customize them to meet the needs of your practice. You may:

  • Modify, delete, or add content

When you have finished customizing the Word file, save it to your desktop or a folder just as you would save any Word document. You may also print it out in the same way.

Forms or Handouts in Adobe® Reader®. Other forms are available in portable document format (PDF) files that require Adobe®Reader® reader for viewing and printing. You may save them to your desktop or a folder and print them as you would a Word file. However, this format does not permit you to customize materials, since some are copyrighted.

After Downloading Materials. To return to the website, close Word or Adobe®Reader®. This will take you back to the Practice Management Resources right where you left off.

Setting Up Your Practice

To prepare your practice for opioid dependence treatment, we recommend that you prepare and educate your staff so that they are comfortable with the new services you provide and their accompanying responsibilities. The resources below are meant to assist you with this.

Back to Top

Working With Pharmacists

The pharmacy professional plays a key role in opioid dependence treatment by helping to ensure that prescriptions for SUBOXONE and other necessary medications are dispensed in a timely manner. These tools are designed to facilitate ongoing treatment.

  • Appointed Pharmacy Consent Form [Word]―By signing this form, the patient authorizes you to disclose to the pharmacy that he or she is being treated for opioid dependence; the pharmacy is also authorized to contact you to discuss treatment
  • Fax Cover Sheet [Word]―For your use, this sheet simplifies access to SUBOXONE from the designated pharmacy

Back to Top

Working With Counselors

Successful treatment for opioid dependence with SUBOXONE includes counseling, which can help the patient to achieve cognitive and behavioral changes. These tools will help you work with counselors for optimum patient progress.

Back to Top

SUBOXONE Treatment Resources

Patient Screening

Careful assessment through screening will help determine if a patient is an appropriate candidate for SUBOXONE medication. These materials will assist you with this process.

Back to Top

Pre-First Visit & Intake

The likelihood of treatment success increases if all procedures and expectations associated with receiving SUBOXONE medication are conveyed to new patients, both verbally and in writing, before they begin treatment. Some of these handouts should be completed in your office; others should be given to patients prior to the first treatment visit.

For office use:

For the patient prior to the first treatment visit:

Back to Top

Induction Resources

When patients begin treatment they need to know what to expect in treatment and be thoroughly evaluated for treatment. The forms below can be used in evaluating patients during intake and induction.

Back to Top

Maintenance Resources

During the maintenance phase, patients should continue to be evaluated for progress and withdrawal symptoms. These forms can be used to help monitor patients.

  • Quality Care Therapy Progress Report [PDF]―This form includes questions based on determining a patient’s progress in treatment. To get a thorough report, there are sections for the patient, counselor, and physician to fill out
  • Appropriate Use Checklist [PDF]―This document serves as a reminder to monitor the appropriate use of SUBOXONE by offering a series of measures to be addressed during each patient’s appointment

Back to Top

Microsoft is a registered trademark of the Microsoft Corporation in the United States and/or other countries.

Adobe Reader is a registered trademark of Adobe Systems Incorporated in the United States and/or other countries.


Important tools for you and your patients



This site is sponsored by Reckitt Benckiser Pharmaceuticals Inc. and intended for residents of the United States.
SUBOXONE® and Here to Help® are registered trademarks of Reckitt Benckiser Healthcare (UK) Ltd.
SUBOXONE® Film is manufactured for Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA 23235 by MonoSol Rx LLC, Warren, NJ 07059
© 2012 Reckitt Benckiser Pharmaceuticals Inc.

Important Safety Information

SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) is indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support. Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.

SUBOXONE Sublingual Film should not be used by patients hypersensitive to buprenorphine or naloxone.

SUBOXONE Sublingual Film can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient's level of stability is essential.

Chronic use of buprenorphine can cause physical dependence. A sudden or rapid decrease in dose may result in an opioid withdrawal syndrome that is typically milder than seen with full agonists and may be delayed in onset.

SUBOXONE Sublingual Film can cause serious life-threatening respiratory depression and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other central nervous system (CNS) depressants (ie, sedatives, tranquilizers, or alcohol). It is extremely dangerous to self-administer nonprescribed benzodiazepines or other CNS depressants while taking SUBOXONE Sublingual Film. Dose reduction of CNS depressants, SUBOXONE Sublingual Film, or both when both are being taken should be considered.

Liver function should be monitored before and during treatment.

Death has been reported in nontolerant, nondependent individuals, especially in the presence of CNS depressants.

Children who take SUBOXONE Sublingual Film can have severe, possibly fatal, respiratory depression. Emergency medical care is critical. Keep SUBOXONE Sublingual Film out of the sight and reach of children.

Intravenous misuse or taking SUBOXONE Sublingual Film before the effects of full-agonist opioids (eg, heroin, hydrocodone, methadone, morphine, oxycodone) have subsided is highly likely to cause opioid withdrawal symptoms.

Neonatal withdrawal has been reported. Use of SUBOXONE Sublingual Film in pregnant women or during breast-feeding should only be considered if the potential benefit justifies the potential risk. Caution should be exercised when driving vehicles or operating hazardous machinery, especially during dose adjustment.

Adverse events commonly observed with the sublingual administration of SUBOXONE Sublingual Film are numb mouth, sore tongue, redness of the mouth, headache, nausea, vomiting, sweating, constipation, signs and symptoms of withdrawal, insomnia, pain, swelling of the limbs, disturbance of attention, palpitations, and blurred vision.

Cytolytic hepatitis, jaundice, and allergic reactions, including anaphylactic shock, have been reported.

This is not a complete list of potential adverse events associated with SUBOXONE Sublingual Film. Please see full Prescribing Information for a complete list.

To report an adverse event associated with taking SUBOXONE Sublingual Film, please call 1-877-782-6966. You are encouraged to report adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see full US prescribing information and Medication Guide for SUBOXONE sublingual film.

For more information about SUBOXONE® (buprenorphine and naloxone) sublingual tablets (CIII), please see full US prescribing information and Medication Guide.

close
close

Map Tips

Close

You are leaving Suboxone.com

Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Clicking on "Continue" will take you to a website that is outside the control of Reckitt Benckiser Pharmaceuticals Inc. You are solely responsible for your interactions with such websites.

Continue Cancel

As always, the information you give us will not be sold or shared with anyone. Please see our privacy policy for more information.

This site makes use of the latest version of the Macromedia Flash Player. Download the player now!

Cancel
The requested information is provided in Portable Document Format (PDF). To view and print this document you'll need to install a copy of the free Adobe® Acrobat® Reader®. If you already have Adobe Acrobat Reader installed click "VIEW PDF" below. If you need the Acrobat Reader you can download it from the Adobe Acrobat Reader Download page.

View PDFCancel

Don't show me this message again.